申请人:Ciba-Geigy
公开号:US05246965A1
公开(公告)日:1993-09-21
The invention relates to the compounds of the formula ##STR1## wherein the C(.dbd.NH)--NHR group may be in tautomeric or isomeric form, and pharmaceutically acceptable salts thereof, in which: R is hydrogen or an acyl radical which is derived from an organic carbonic acid, an organic carboxylic acid, a sulfonic acid, or a carbamic acid; R.sub.1 is a substituent selected from an aliphatic hydrocarbon radical, an araliphatic hydrocarbon radical and a cycloaliphatic hydrocarbon radical; X.sub.1 and X.sub.3, independently of one another, are oxygen (--O--) or sulphur (--S--); and X.sub.2 is a divalent aliphatic hydrocarbon radical which may be interrupted by an aromatic radical; wherein the phenyl rings of formula I may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid; wherein aryl in the above definitions may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid; and wherein a cycloaliphatic hydrocarbon radical may be substituted by an aliphatic radical. The compounds are useful as selective LTB.sub.4 receptor antagonists in the treatment of conditions or syndromes in mammals which are responsive to LTB.sub.4 receptor antagonism.
本发明涉及以下式的化合物:##STR1##其中C(.dbd.NH)--NHR基团可以处于互变异构或同分异构形式,并且其药学上可接受的盐,其中:R是氢或由有机碳酸、有机羧酸、磺酸或氨基甲酸导出的酰基基团;R.sub.1是从脂肪烃基、芳基脂肪烃基和环烷基脂肪烃基中选择的取代基;X.sub.1和X.sub.3,独立地,是氧(--O--)或硫(--S--);X.sub.2是二价的脂肪烃基,可以被芳香基团中断;其中式I的苯环可以独立地进一步被一个或多个取代基所取代,所述取代基从卤素、三氟甲基、脂肪烃基、羟基、被脂肪烷基、芳基脂肪烷基或环烷基醇乙醚化的羟基或被脂肪烷基或芳基脂肪酸酯化的羟基中选择;其中上述定义中的芳基可以独立地进一步被一个或多个取代基所取代,所述取代基从卤素、三氟甲基、脂肪烃基、羟基、被脂肪烷基、芳基脂肪烷基或环烷基醇乙醚化的羟基或被脂肪烷基或芳基脂肪酸酯化的羟基中选择;其中环烷基脂肪烃基可以被脂肪烃基所取代。该化合物可用作选择性LTB.sub.4受体拮抗剂,用于响应于LTB.sub.4受体拮抗的哺乳动物的病症或综合征的治疗。